Whalesbook
Apollo Hospitals' Demerger Plans Boost Valuation Hopes
Prabhudas Lilladher has maintained its 'BUY' recommendation for Apollo Hospitals Enterprise, increasing its price target to ₹9,350. The brokerage's optimism stems from the company's solid financial performance, reporting a consolidated EBITDA of ₹10.1 billion, which surpassed estimates by 5% and showed a 31% rise year-over-year. Even after accounting for specific costs, the adjusted EBITDA reached ₹11.1 billion, a 19% increase from the previous year.
Key to the brokerage's positive view are the strategic divestments, including the sale of its HealthCo stake to Advent and its merger with Keimed. These moves are paving the way for a comprehensive pharmacy and digital health ecosystem. Furthermore, Apollo Hospitals plans to demerge its '24*7' omnichannel pharmacy business and telehealth services into a separate, publicly traded company. This separation is expected to unlock significant shareholder value by allowing these focused, consumer-oriented operations to pursue their own growth paths. The digital segment is reportedly close to reaching profitability in the coming quarters.
Growth Projections and Market Position
Looking ahead, Prabhudas Lilladher forecasts a strong 25% EBITDA compound annual growth rate (CAGR) for Apollo Hospitals Enterprise between fiscal years 2026 and 2028. This projection includes a slight 2% upward adjustment to EBITDA estimates for FY27 and FY28. The valuation model uses a 25x EV/EBITDA multiple for the hospital and offline pharmacy operations, and a 20x EV/EBITDA multiple for the AHLL business, acknowledging the distinct growth potential across these divisions.
In the broader healthcare market, competitors like Fortis Healthcare and Max Healthcare are also pursuing strategic initiatives such as capacity expansion and digital integration. However, Apollo's decision to demerge its consumer-focused digital and pharmacy businesses positions it to potentially capture specific market segments more effectively. While sector-wide analyst sentiment favors companies showing clear strategies for margin improvement and efficient capital use, Apollo's move targets specialized growth.
Potential Risks and Challenges
Despite the positive outlook, investors should be aware of potential risks. The success of the demerger depends on efficient execution and the ability of the new entities to achieve their growth targets without affecting the core hospital business. Market volatility, driven by regulatory changes or shifts in government healthcare policies, could also impact profitability. The integration process for HealthCo and Keimed, while strategic, carries execution risks. Any delays or unexpected issues could reduce the anticipated benefits.
Investors will also need to watch how other integrated healthcare providers respond and monitor the fast-evolving digital health landscape, which requires ongoing innovation and investment.
Focused Future Strategy
The strategic realignment, particularly the demerger of its pharmacy and digital health operations, signals Apollo Hospitals' commitment to enhancing focus and unlocking hidden value. The company's performance from fiscal years 2026 to 2028 is expected to show accelerated EBITDA growth, fueled by its hospital segment and its developing digital health platform. The market will be closely observing how the demerged businesses establish themselves as independent growth drivers in India's expanding healthcare and pharmaceutical sectors.